State Street’s Rani Therapeutics RANI Stock Holding History

State Street’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$274K	Sell	373,142 -13,900	-4%	-$17.8K	﹤0.01%	3816
2025 Q4	$523K	Buy	387,042 +324,600	+520%	+$490K	﹤0.01%	3664
2025 Q3	$31.2K	Hold	62,442	–	–	﹤0.01%	4210
2025 Q2	$32.1K	Hold	62,442	–	–	﹤0.01%	4159
2025 Q1	$78.7K	Hold	62,442	–	–	﹤0.01%	4020
2024 Q4	$85.5K	Buy	62,442 +20,400	+49%	+$42.9K	﹤0.01%	4020
2024 Q3	$90.8K	Hold	42,042	–	–	﹤0.01%	3992
2024 Q2	$160K	Buy	42,042 +8,300	+25%	+$43K	﹤0.01%	3879
2024 Q1	$105K	Hold	33,742	–	–	﹤0.01%	4026
2023 Q4	$112K	Hold	33,742	–	–	﹤0.01%	4036
2023 Q3	$73.4K	Buy	33,742 +1,800	+6%	+$6.88K	﹤0.01%	4188
2023 Q2	$132K	Hold	31,942	–	–	﹤0.01%	4139
2023 Q1	$165K	Hold	31,942	–	–	﹤0.01%	4138
2022 Q4	$188K	Buy	31,942 +5,800	+22%	+$42.3K	﹤0.01%	4127
2022 Q3	$250K	Hold	26,142	–	–	﹤0.01%	4039
2022 Q2	$270K	Hold	26,142	–	–	﹤0.01%	4079
2022 Q1	$353K	Buy	26,142 +6,442	+33%	+$107K	﹤0.01%	4183
2021 Q4	$322K	Hold	19,700	–	–	﹤0.01%	4164
2021 Q3	$351K	Buy	+19,700	New	+$341K	﹤0.01%	4116

Other funds holding RANI

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCP

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

State Street's RANI Position: Q1 2026 in Review

State Street reduced its Rani Therapeutics (RANI) stake by 3.6% in Q1 2026, selling an estimated $17.8K and leaving 373,142 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #3816.

State Street first reported a position in RANI in Q3 2021 and has held it in 19 quarters since. The position peaked at $523K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

State Street held 373,142 shares of Rani Therapeutics worth $274K as of Q1 2026.
State Street sold 13,900 Rani Therapeutics shares in Q1 2026, an estimated $17.8K.
Rani Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3816 holding.
State Street first reported a position in Rani Therapeutics in Q3 2021 and has held it in 19 quarters since.
State Street's Rani Therapeutics position peaked at $523K in Q4 2025.
74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.